Physician profile
Purvi K Shah
NPI 1275580722
$8,725.31
in general payments reported to CMS, 2019-2025
60 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what 97% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2021: $50.87 · 2022: $731 · 2023: $3,137 · 2024: $2,411 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,874 · Travel and Lodging: $1,220 · Education: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,874.25 |
| Travel and Lodging | $1,219.60 |
| Education | $645.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $1,390.97 | 2023 | |
| Novartis Pharmaceuticals Corporation | $746.25 | 2019-2025 | |
| Astellas Pharma US INC | $608.72 | 2022-2025 | Xospata, Vyloy, Padcev |
| Astrazeneca Pharmaceuticals Lp | $530.76 | 2021-2025 | Lynparza, Calquence, Tagrisso |
| Merck Sharp & Dohme LLC | $415.85 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $402.07 | 2019-2025 | |
| Genentech USA, INC. | $314.86 | 2022-2025 | Tecentriq, Rozlytrek, Avastin |
| E.R. Squibb & Sons, L.L.C. | $312.41 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Eisai INC. | $289.27 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $254.33 | 2022-2025 | Onivyde, Somatuline Depot |
| Incyte Corporation | $244.13 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Janssen Biotech, INC. | $225.58 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Tersera Therapeutics LLC | $199.69 | 2023-2025 | Xermelo, Zoladex, Quzyttir |
| Abbvie INC. | $196.65 | 2023-2025 | Venclexta |
| Sanofi-Aventis U.S. LLC | $184.94 | 2022-2023 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $150.94 | 2019-2025 | Fruzaqla, Ninlaro |
| Bayer Healthcare Pharmaceuticals INC. | $133.23 | 2022-2025 | |
| Amgen INC. | $125.28 | 2022-2023 | Lumakras, Nplate, Xgeva |
| Glaxosmithkline, LLC. | $119.78 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Taiho Oncology, INC. | $113.41 | 2022-2025 | |
| Gilead Sciences, INC. | $107.64 | 2021-2025 | Trodelvy |
| Karyopharm Therapeutics INC. | $101.93 | 2023-2025 | Xpovio |
| Seagen INC. | $97.03 | 2019-2023 | Adcetris |
| Puma Biotechnology, INC. | $96.00 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.95 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $71.29 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $68.90 | 2022-2023 | Imbruvica, Epkinly |
| Servier Pharmaceuticals LLC | $68.67 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $68.36 | 2023-2025 | Libtayo |
| Celgene Corporation | $64.99 | 2023-2024 | Pomalyst, Reblozyl |
| Deciphera Pharmaceuticals INC. | $62.58 | 2023-2025 | Qinlock, Romvimza |
| Pharmacosmos Therapeutics INC. | $61.39 | 2023-2025 | Monoferric |
| Alnylam Pharmaceuticals INC. | $60.84 | 2022-2024 | Givlaari |
| Progenics Pharmaceuticals, INC. | $57.85 | 2024-2025 | |
| Daiichi Sankyo INC. | $50.08 | 2022-2025 | Enhertu |
| Pharmaessentia USA Corporation | $48.90 | 2023-2024 | Besremi |
| Kite Pharma, INC. | $45.53 | 2022-2023 | Yescarta |
| Sobi, INC | $44.08 | 2024 | |
| Beone Medicines USA, INC. | $41.52 | 2025 | Brukinsa |
| Genzyme Corporation | $38.28 | 2022 | |
| Array Biopharma INC | $36.01 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Emd Serono, INC. | $35.10 | 2023-2025 | Bavencio |
| Caris Mpi, INC. | $31.57 | 2025 | Mi Cancer Seek |
| Agios Pharmaceuticals, INC. | $31.23 | 2024-2025 | Pyrukynd |
| Geron Corporation | $26.31 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $23.44 | 2023 | Orserdu |
| Exelixis INC. | $23.38 | 2025 | Cabometyx |
| Mirati Therapeutics, INC. | $23.23 | 2023 | Krazati |
| Beigene USA, INC. | $21.81 | 2023 | Brukinsa |
| Genmab U.S., INC. | $20.76 | 2024 | Epkinly |
| G1 Therapeutics, INC. | $20.29 | 2022 | |
| Adc Therapeutics America, INC. | $18.50 | 2025 | |
| Aveo Pharmaceuticals, INC. | $18.25 | 2025 | |
| Coherus Oncology, INC. | $18.07 | 2023 | |
| Recordati_rare_diseases_inc. | $17.79 | 2023 | Sylvant |
| Lilly USA, LLC | $15.82 | 2023 | Retevmo, Verzenio, Jaypirca |
| Legend Biotech USA INC. | $15.73 | 2025 | Carvykti |
| Apellis Pharmaceuticals, INC. | $15.57 | 2024 | Empaveli |
| Janssen Pharmaceuticals, INC | $11.29 | 2019 | |
| Rigel Pharmaceuticals, INC. | $6.23 | 2023 | Rezlidhia, Tavalisse |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Purvi Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.